MedTrace Logo

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

NCT00384176 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1814

Last updated 2017-04-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.

Conditions

Interventions

DRUG

Cediranib

oral tablet once daily

DRUG

Bevacizumab

intravenous infusion

DRUG

5-fluorouracil ( in FOLFOX)

intravenous infusion

DRUG

Leucovorin (in FOLFOX)

intravenous infusion

DRUG

Oxaliplatin (in FOLFOX)

intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Jane Robertson · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-30
Primary Completion
2009-11-15
Completion
2015-08-19

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • Czechia
  • Egypt
  • Finland
  • France
  • Germany
  • Hungary
  • India
  • Israel
  • Italy
  • Latvia
  • Malta
  • Philippines
  • Poland
  • Russia
  • Slovakia
  • South Africa
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00384176 on ClinicalTrials.gov